Abstract:Background: Even with long-term complete suppression of the virus through Antiretroviral therapy (ART), people infected with HIV cannot attain optimal immune reconstitution. This phenomenon is called immune reconstitution deficiency, there are no effective therapeutic interventions for immune reconstitution deficiency in modern medicine. Objective: To evaluate the efficacy and safety of ART with Shenling Guben Granules Traditional Chinese medicine in boosting immunological reconstitution compared with ART alone. Methods: This was a randomized, double-blind, placebo-controlled, multi-center clinical trial evaluating the efficacy and safety of ART combined with Chinese medicine. The individuals aged 18–65 years with poor immune reconstitution following ART were included in this trial. The primary outcome was a change in the absolute value of CD4+ T lymphocytes after 72 weeks of combined ART and Chinese medicine administration. Secondary outcomes included changes in CD4+ T lymphocyte functional subpopulations, activated T lymphocyte subpopulations, CD4+ T lymphocyte proliferation, and T lymphocyte apoptosis from baseline to after 72 weeks. We also evaluated efficacy at 24- and 48-week intervals to better understand the dynamics of the trial drug’s efficacy. Results: There was a significant increase in CD4+ cell counts in groups treated with the Shenling Guben Granules after 24 weeks, 48 weeks, and 72 weeks of treatment (P<0.05), and the difference in CD4+ cell counts at 24 weeks of treatment was statistically significant (P=0.010). After 48 and 72 weeks of therapy, the CD4+CD38+ cell counts in the Shenling Guben Granules group were significantly higher than in the control group (P<0.05). In the subgroup analysis of CD4+ cell counts ≥200 cells/mm3, the CD4+ cell counts in the treatment group were higher than the control group after treatment for 24, 48, and 72 weeks (P<0.05). Discussion: CD4 cell counts in HIV/AIDS patients with immunological reconstitution insufficiency can be improved to a certain extent using Shenling Guben Granules. The greater the CD4 cell count at the start, the better the therapy response. Furthermore, Shenling Guben Granules have the efficacy and safety to prevent aberrant immunological activation. A large sample size, long-term follow-up, and multiple efficacy indicators were employed to assess the therapy’s safety. Our findings will lead to new therapeutic alternatives for HIV/AIDS patients suffering from immune reconstitution deficiency. Clinical Trial Registry: Name of the registry: Sundy on promote the reconstruction of Inadequate responders in HIV/AIDS patients after combined antiretroviral therapy by Shen Ling Gu Ben Granules;Chictr.org.cn Identifier: ChiCTR1800015290, registered on March 21, 2018( http://www.chictr.org.cn/registry.aspx).

Treg Cell Evaluation in Patients with Acquired Immune Deficiency Syndrome with Poor Immune Reconstitution and Human Immunodeficiency Virus-Infected Treg Cell Prevention by Polymeric Nanoparticle Drug Delivery System.

Study on the application of CD4+ T lymphocyte rapid detection method in treating AIDS

The Serum Levels and Roles of Regulated Upon Activation Normal T Cell Expressed and Secreted and Monocyte Chemoattractant Protein-1 in Human Immunodeficiency Virus-1 Infected Patients

Recent advances in poor HIV immune reconstitution: what will the future look like?

Co-Delivery of Hiv-1 Entry Inhibitor and Nonnucleoside Reverse Transcriptase Inhibitor Shuttled by Nanoparticles: Cocktail Therapeutic Strategy for Antiviral Therapy

D-α-Tocopheryl Polyethylene Glycol Succinate-decorated dual drug-loaded lipidic nanocarriers: A Strategic approach for targeting lymphatic uptake and p-gp efflux modulation to enhance oral bioavailability in HIV-1 viral reservoirs

Enhanced immune reconstitution with albuvirtide in HIV-infected immunological non-responders

Antiretroviral Drugs-Loaded Nanoparticles Fabricated by Dispersion Polymerization with Potential for HIV/AIDS Treatment

Reversal of the CD8+ T-Cell Exhaustion Induced by Chronic HIV-1 Infection Through Combined Blockade of the Adenosine and PD-1 Pathways

Use of Programmed Cell Death Protein 1 (PD-1) Inhibitor Therapy in HIV-infected Patients with Advanced Cancer: a Single-Center Study from China

Antiretroviral Therapy Combined with Shenling Guben Granules for the Treatment of HIV Infection with Immune Reconstitution Deficiency: A Randomized, Double-Blind, Placebo-Controlled Study

Advances in Mechanism of HIV-1 Immune Reconstitution Failure: Understanding Lymphocyte Subpopulations and Interventions for Immunological Nonresponders

Therapeutic strategies for immune reconstitution in acquired immunodeficiency syndrome

[Enhancing immune restoration in human immunodeficiency virus infection]

Comprehensive transcriptomic analyses identify the immunosuppressive effects of LLDT-8 in ART-treated SIV-infected rhesus macaques

Systemic Administration of Combinatorial Dsirnas Via Nanoparticles Efficiently Suppresses HIV-1 Infection in Humanized Mice

Persistently Elevated Expression of Systemic, Soluble Co-Inhibitory Immune Checkpoint Molecules in People Living with HIV before and One Year after Antiretroviral Therapy

Evaluating the Use of Sacran, a Polysaccharide Isolated from Aphanothece sacrum, as a Possible Microbicide for Preventing HIV-1 Infection

Combined Dendritic Cell And Anti-TIGIT Immunotherapy Potentiate Trail+ Memory NK Cells Against HIV-1 Infected Cells

Adjunct Therapy for CD4+ T-Cell Recovery, Inflammation and Immune Activation in People Living With HIV: A Systematic Review and Meta-Analysis

Decreased CD73+ Double-Negative T Cells and Elevated Level of Soluble CD73 Correlated With and Predicted Poor Immune Reconstitution in HIV-Infected Patients After Antiretroviral Therapy